Gideon Charach1, Itamar Grosskopf, Moshe Weintraub. 1. Department of Internal Medicine C, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. drcharach@012.net.il
Abstract
BACKGROUND: Copaxone (glatiramer acetate) is a synthetic copolymer mimicking a portion of myelin basic protein, one of several putative autoantigens in multiple sclerosis (MS). Copaxone suppresses the production of tumor necrosis factor (TNF)-alpha, a key mediator of inflammation in MS as well as in other pathologies, such as colitis of interstitial bowel disease (IBD). Copaxone is a drug approved for the treatment of MS, and one that is very well tolerated with a high safety profile and relatively few side effects. Crohn's disease has not been associated with its administration. METHODS: We describe a patient with MS in remission who had not exhibited any signs of IBD in the past. She had been on Copaxone 20 mg/day treatment for 2 years when she first exhibited gastrointestinal symptoms. RESULTS: Our patient developed Crohn's disease while on Copaxone treatment as a consequence of long-term immunosuppression. CONCLUSIONS: Clinicians should be aware that Crohn's disease is a potential novel adverse drug effect of Copaxone. Copyright 2008 S. Karger AG, Basel.
BACKGROUND:Copaxone (glatiramer acetate) is a synthetic copolymer mimicking a portion of myelin basic protein, one of several putative autoantigens in multiple sclerosis (MS). Copaxone suppresses the production of tumor necrosis factor (TNF)-alpha, a key mediator of inflammation in MS as well as in other pathologies, such as colitis of interstitial bowel disease (IBD). Copaxone is a drug approved for the treatment of MS, and one that is very well tolerated with a high safety profile and relatively few side effects. Crohn's disease has not been associated with its administration. METHODS: We describe a patient with MS in remission who had not exhibited any signs of IBD in the past. She had been on Copaxone 20 mg/day treatment for 2 years when she first exhibited gastrointestinal symptoms. RESULTS: Our patient developed Crohn's disease while on Copaxone treatment as a consequence of long-term immunosuppression. CONCLUSIONS: Clinicians should be aware that Crohn's disease is a potential novel adverse drug effect of Copaxone. Copyright 2008 S. Karger AG, Basel.
Authors: Niannian Ji; Animesh Somanaboeina; Aakanksha Dixit; Kazuyuki Kawamura; Neil J Hayward; Christopher Self; Gary L Olson; Thomas G Forsthuber Journal: J Immunol Date: 2013-10-11 Impact factor: 5.422
Authors: Bu'Hussain Hayee; Farooq Z Rahman; Gavin Sewell; Andrew M Smith; Anthony W Segal Journal: Expert Rev Clin Immunol Date: 2010-07 Impact factor: 4.473
Authors: Andrew M Smith; Farooq Z Rahman; Bu'Hussain Hayee; Simon J Graham; Daniel J B Marks; Gavin W Sewell; Christine D Palmer; Jonathan Wilde; Brian M J Foxwell; Israel S Gloger; Trevor Sweeting; Mark Marsh; Ann P Walker; Stuart L Bloom; Anthony W Segal Journal: J Exp Med Date: 2009-08-03 Impact factor: 14.307